ECSP055530A - Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva - Google Patents

Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva

Info

Publication number
ECSP055530A
ECSP055530A EC2005005530A ECSP055530A ECSP055530A EC SP055530 A ECSP055530 A EC SP055530A EC 2005005530 A EC2005005530 A EC 2005005530A EC SP055530 A ECSP055530 A EC SP055530A EC SP055530 A ECSP055530 A EC SP055530A
Authority
EC
Ecuador
Prior art keywords
preparations
relates
substituted
stratriens
strateges
Prior art date
Application number
EC2005005530A
Other languages
English (en)
Spanish (es)
Inventor
Dirk Kosemund
Gerd Mueller
Alexander Hillisch
Karl-Heinrich Fritzemeier
Peter Muhn
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of ECSP055530A publication Critical patent/ECSP055530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EC2005005530A 2002-06-11 2005-01-10 Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva ECSP055530A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10226326A DE10226326A1 (de) 2002-06-11 2002-06-11 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene

Publications (1)

Publication Number Publication Date
ECSP055530A true ECSP055530A (es) 2005-03-10

Family

ID=29723144

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005530A ECSP055530A (es) 2002-06-11 2005-01-10 Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva

Country Status (28)

Country Link
EP (1) EP1517914B1 (enExample)
JP (1) JP4615998B2 (enExample)
KR (1) KR101006612B1 (enExample)
CN (1) CN1293090C (enExample)
AR (1) AR040188A1 (enExample)
AT (1) ATE303397T1 (enExample)
AU (1) AU2003242683B9 (enExample)
BR (1) BR0312140A (enExample)
CA (1) CA2486495C (enExample)
CR (1) CR10289A (enExample)
CU (1) CU23414B7 (enExample)
DE (2) DE10226326A1 (enExample)
DK (1) DK1517914T3 (enExample)
EA (1) EA008442B1 (enExample)
EC (1) ECSP055530A (enExample)
ES (1) ES2248770T3 (enExample)
HR (1) HRP20050009B1 (enExample)
IL (1) IL165321A (enExample)
MX (1) MXPA04012491A (enExample)
NO (1) NO329563B1 (enExample)
PE (1) PE20040613A1 (enExample)
PL (1) PL209910B1 (enExample)
RS (1) RS50878B (enExample)
TW (1) TWI286140B (enExample)
UA (1) UA78062C2 (enExample)
UY (1) UY27844A1 (enExample)
WO (1) WO2003104253A2 (enExample)
ZA (1) ZA200500217B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10027887A1 (de) 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP1689410B1 (en) * 2003-11-26 2008-05-21 Bayer Schering Pharma Aktiengesellschaft Prevention and treatment of hypertensive heart diseases by the selective estrogens 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol and 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
US7534780B2 (en) 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
DE102005057224A1 (de) * 2005-11-29 2007-05-31 Bayer Schering Pharma Ag Prodrugs ERß-selektiver Substanzen, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
EP2252261A2 (en) * 2008-02-13 2010-11-24 Bayer Schering Pharma Aktiengesellschaft Drug delivery system with stabilising effect
EP2143432A1 (en) 2008-07-11 2010-01-13 Bayer Schering Pharma AG 9-alpha estratriene derivatives as ER-beta selective ligands for the prevention and treatment of intestinal cancer
WO2010057594A1 (en) * 2008-11-21 2010-05-27 Bayer Schering Pharma Aktiengesellschaft Drug delivery system
EP3185881B1 (en) 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
CA3109978A1 (en) * 2018-09-07 2020-03-12 Trustees Of Dartmouth College C19 scaffolds and steroids and methods of use and manufacture thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
US6154158A (en) * 1998-06-30 2000-11-28 Qualcomm Incorporated Digital-to-analog converter D.C. offset correction comparing converter input and output signals
DE19906159A1 (de) * 1999-02-09 2000-08-10 Schering Ag 16-Hydroxyestratriene als selektiv wirksame Estrogene
EP1226155B1 (de) * 1999-11-02 2007-05-02 Bayer Schering Pharma AG 18-nor-steroide als selektiv wirksame estrogene
AU5834101A (en) * 2000-04-12 2001-10-23 Schering Ag 8ss-hydrocarbyl-substituted estratrienes for use as selective estrogens

Also Published As

Publication number Publication date
CA2486495C (en) 2011-04-19
TWI286140B (en) 2007-09-01
PL373090A1 (en) 2005-08-08
HRP20050009B1 (hr) 2013-07-31
ES2248770T3 (es) 2006-03-16
AU2003242683A1 (en) 2003-12-22
NO20050127L (no) 2005-03-11
WO2003104253A2 (de) 2003-12-18
ZA200500217B (en) 2006-03-29
DE10226326A1 (de) 2004-01-15
CN1659181A (zh) 2005-08-24
JP4615998B2 (ja) 2011-01-19
CN1293090C (zh) 2007-01-03
KR20050009745A (ko) 2005-01-25
DK1517914T3 (da) 2006-01-16
AU2003242683B2 (en) 2009-07-02
NO20050127D0 (no) 2005-01-10
NO329563B1 (no) 2010-11-15
HRP20050009A2 (en) 2005-04-30
PE20040613A1 (es) 2004-12-01
KR101006612B1 (ko) 2011-01-10
HK1081203A1 (en) 2006-05-12
PL209910B1 (pl) 2011-11-30
TW200407331A (en) 2004-05-16
UA78062C2 (en) 2007-02-15
IL165321A (en) 2009-08-03
CR10289A (es) 2008-11-26
EP1517914A2 (de) 2005-03-30
CU23414B7 (es) 2009-09-08
UY27844A1 (es) 2003-12-31
CA2486495A1 (en) 2003-12-18
DE50301116D1 (de) 2005-10-06
MXPA04012491A (es) 2005-06-08
RS50878B (sr) 2010-08-31
RS107004A (sr) 2006-10-27
EA008442B1 (ru) 2007-06-29
AU2003242683B9 (en) 2009-08-27
AR040188A1 (es) 2005-03-16
JP2005533053A (ja) 2005-11-04
EP1517914B1 (de) 2005-08-31
BR0312140A (pt) 2005-04-05
WO2003104253A3 (de) 2004-09-16
EA200401544A1 (ru) 2005-06-30
ATE303397T1 (de) 2005-09-15

Similar Documents

Publication Publication Date Title
DK1272505T3 (da) 8beta-substituerede-11beta-pentyl- og 11beta-hexyl-estra-1,3,5(10)-trienderivater
GT199800021A (es) Utilizacion de antagonistas de los receptores de canabinoides centrales para la preparacion de medicamentos.
CR7611A (es) Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona
HRP20050781B1 (hr) Metode i farmaceutske mješavine za pouzdano postizanje prihvatljivih razina testosterona u serumu
CR10289A (es) "estratrienos 9-alfa-sustituidos como estrogenos de eficacia selectiva"(divisional)
EA200600029A1 (ru) Фармацевтическая композиция для контрацепции и заместительной гормональной терапии
PE20040068A1 (es) Decanoato, undecanoato y dodecanoato de etonogestrel
PA8613001A1 (es) Derivados de triazol sustituidos como antagonistas de oxitocina
PE20070188A1 (es) Formulaciones de estrogenos conjugados y bazedoxifeno
AR034392A1 (es) Compuestos derivados de 3, 16-dihidroxi-estra-1,3,5(10)-trieno, empleo de los mismos y de partes estructurales de los mismos y composiciones farmaceuticas que los contienen
UY26665A1 (es) Estratrienos sustituidos como estrógenos selectivamente activos
ECSP109872A (es) Estratrienos 8-beta-sustituidos como estrógenos de acción selectiva
PE20020466A1 (es) Combinacion de raloxifeno y exemestano para el tratamiento de cancer de mama
PE20050207A1 (es) Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros referida a enfermedades dependientes de hormonas
HRP20090256T1 (en) Use of estradiolvalerate and dienogest for oral treatment of dysfunctional uterine bleeding in a contraceptive method
UY26967A1 (es) Derivados 8beta-sustituidos de 11beta-pentil y 11beta-hexil-estra-1,3,5(10)-trieno.-
AR036227A1 (es) USO DE LIGANDOS SELECTIVOS PARA ERa PARA REGULAR LA FERTILIDAD.
TH114620A (th) 8-บีตา-ซับสทิทิวเทด เอสทราไทรอีนที่เป็นเอสโทรเจนที่ออกฤทธิ์อย่างมีอำนาจเลือก
AR033260A1 (es) Nueva composicion hormonal y su utilizacion
AR035590A1 (es) Derivados 8 beta-sustituidos de 11beta-pentil- y 11beta-hexil-estra-1,3,5 (10)-trieno, las composiciones farmaceuticas que los contienen y el uso de estos derivados para preparar medicamentos
ES2177421B1 (es) Composicion para el tratamiento de trastornos por ingesta de alcohol y similares y su procedimiento de preparacion.
PE20020520A1 (es) Uso de antiprogestinas para la profilaxis y el tratamiento de enfermedades dependientes de hormonas
PE20030411A1 (es) DERIVADOS 8ß-SUSTITUIDOS DE 11ß-FENIL Y 11ß-HEXIL-ESTRA-1,3,5(10)-TRIENO QUE TIENEN AFINIDAD POR RECEPTORES DE ESTROGENO
AR030018A1 (es) Derivados de benzo(d)(1,3)oxazin-2-ona, composiciones farmaceuticas que los comprenden y el uso de los mismos para preparar medicamentos como moduladores receptores de progesterona
AR044184A1 (es) Metodo para el manejo terapeutico de la proliferacion extrauterina de tejido endometrial, dolor pelvico cronico y obstruccion de las trompas de falopio, las composiciones farmaceuticas utiles para la aplicacion de dicho metodo y el uso de un antagonista de lhrh para la preparacion de dichos medicame